FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody or its antigen-binding fragment that specifically binds to the C-X-C-chemokine 5 receptor (CXCR5), to a composition containing it, as well as to a method for producing it. Also an isolated nucleic acid encoding the above antibody or a fragment thereof, as well as a vector and a cell containing it are disclosed. The invention also relates to a method for detecting CXCR5 in a sample, tissue or cell, using the above antibody or a fragment thereof.
EFFECT: invention is effective for the treatment or prevention of an immunological disease, disorder or condition mediated by CXCR5.
47 cl, 9 dwg, 16 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| ILT7 BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2756109C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
